Generation of pseudo-CT from a single MRI for PET/MR attenuation correction purposes

Quantitative Assessment of Myocardial Ischemia With Positron Emission Tomography

Recent advances in positron emission tomography (PET) technology and reconstruction techniques have now made quantitative assessment using cardiac PET readily available in most cardiac PET imaging centers. Multiple PET myocardial perfusion imaging (MPI) radiopharmaceuticals are available for quantitative examination of myocardial ischemia, with each having distinct convenience and accuracy profile. Important properties of these radiopharmaceuticals ( 15 O-water, 13 N-ammonia, 82 Rb, 11 C-acetate, and 18 F-flurpiridaz) including radionuclide half-life, mean positron range in tissue, and the relationship between kinetic parameters and myocardial blood flow (MBF) are presented. Absolute quantification of MBF requires PET MPI to be performed with protocols that allow the generation of dynamic multiframes of reconstructed data. Using a tissue compartment model, the rate constant that governs the rate of PET MPI radiopharmaceutical extraction from the blood plasma to myocardial tissue is calculated. Then, this rate constant ( K1 ) is converted to MBF using an established extraction formula for each radiopharmaceutical. As most of the modern PET scanners acquire the data only in list mode, techniques of processing the list-mode data into dynamic multiframes are also reviewed. Finally, the impact of modern PET technologies such as PET/CT, PET/MR, total-body PET, machine learning/deep learning on comprehensive and quantitative assessment of myocardial ischemia is briefly described in this review.

Dosimetric evaluation of an atlas-based synthetic CT generation approach for MR-only radiotherapy of pelvis anatomy

PURPOSE

To investigate the potential of an atlas-based approach in generation of synthetic CT for pelvis anatomy.

METHODS

Twenty-three matched pairs of computed tomography (CT) and magnetic resonance imaging (MRI) scans were selected from a pool of prostate cancer patients. All MR scans were preprocessed to reduce scanner- and patient-induced intensity inhomogeneities and to standardize their intensity histograms. Ten (training dataset) of 23 pairs were then utilized to construct the coregistered CT-MR atlas. The synthetic CT for a new patient is generated by appropriately weighting the deformed atlas of CT-MR onto the new patient MRI. The training dataset was used as an atlas to generate the synthetic CT for the rest of the patients (test dataset). The mean absolute error (MAE) between the deformed planning CT and synthetic CT was computed over the entire CT image, bone, fat, and muscle tissues. The original treatment plans were also recomputed on the new synthetic CTs and dose-volume histogram metrics were compared. The results were compared with a commercially available synthetic CT Software (MRCAT) that is routinely used in our clinic.

RESULTS

MAE errors (±SD) between the deformed planning CT and our proposed synthetic CTs in the test dataset were 47 ± 5, 116 ± 12, 36 ± 6, and 47 ± 5 HU for the entire image, bone, fat, and muscle tissues respectively. The MAEs were 65 ± 5, 172 ± 9, 43 ± 7, and 42 ± 4 HU for the corresponding tissues in MRCAT CT. The dosimetric comparison showed consistent results for all plans using our synthetic CT, deformed planning CT and MRCAT CT.

CONCLUSION

We investigated the potential of a multiatlas approach to generate synthetic CT images for the pelvis. Our results demonstrate excellent results in terms of HU value assignment compared to the original CT and dosimetric consistency.